History
2013
Founded by Amir Jafri
January 2014
Terumo BCT, an industry-leading manufacturer of therapeutic apheresis equipment, and Immunicom enter into a strategic partnership
May 2014
Start of pre-clinical canine trial
December 2015
Completed a $5.5M Series A Preferred Stock financing
February 2016
The pre-clinical canine cancer trial ended, achieving 300 Immunopheresis treatments. Overall, 50-60% of the canine patients treated were observed to have either a stable disease or partial response. One canine experienced a complete response with clearance of metastases.
December 2017
University of California San Diego and Immunicom entered an exclusive licensing agreement to co-develop targeted molecule delivery technology
May 2018
The U.S. FDA awards Immunicom Breakthrough Device Designation for the treatment of cancer
August 2018
Immunicom leaders co-authored peer reviewed article in The Journal of Translational Medicine on unleashing TNF-alpha as a cancer immunotherapeutic
June 2019
First patient enrolled in a multi-center clinical trial at University of Krakow to investigate the outcomes of Immunopheresis as a treatment for patients with triple negative breast cancer
July 2019
Immunicom hosted the First Annual Global Immunopheresis Conference in Krakow, Poland
May 2020
The ImmunopheresisTM LW-02 column received regulatory clearance (CE Mark certification) in Europe for use in adults with advanced, refractory triple negative breast cancer (TNBC)
July 2020
First patient enrolled in a clinical trial at Sheba Medical Center to investigate the outcomes of ImmunopheresisTM as a monotherapy and combination therapy. The trial is assessing metastatic melanoma, triple negative breast cancer, renal cell carcinoma and non-small cell lung cancer
Get in touch today
Let’s talk about what we can achieve together
Learn more about
our team
our team